Price T Rowe Associates Inc Igm Biosciences, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,568,999 shares of IGMS stock, worth $4.96 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,568,999
Previous 4,014,259
11.09%
Holding current value
$4.96 Million
Previous $66.4 Million
67.16%
% of portfolio
0.0%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding IGMS
# of Institutions
86Shares Held
19.5MCall Options Held
61.3KPut Options Held
36.7K-
Baker Bros. Advisors LP New York, NY4.09MShares$5.69 Million0.28% of portfolio
-
Siren, L.L.C. New York, NY3.33MShares$4.63 Million0.9% of portfolio
-
Redmile Group, LLC San Francisco, CA2.95MShares$4.1 Million1.41% of portfolio
-
Goldman Sachs Group Inc New York, NY978KShares$1.36 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA896KShares$1.25 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $40.3M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...